What You Should Know:
– Arkin Capital, a leading multi-asset investment manager, today announced the closing of Arkin Bio Ventures III, a $100 million fund focused on investing in advanced pre-clinical and early clinical-stage biotech companies developing transformative therapies in areas of high unmet medical need.
– The fund is backed by top-tier institutional investors, including Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, alongside a significant investment from Arkin Capital itself.
Arkin Bio Launches Ventures III, Doubling Down on Biology-First Biotech Investing
Arkin Capital operates as a diversified global investment manager with more than $2 billion in assets under management across 12 funds. The platform deploys capital through four primary investment arms—Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate—with healthcare and life sciences representing a core strength built over more than 15 years.
Across its portfolio, Arkin Capital has achieved over 20 successful exits, reflecting a consistent, cross-sector track record. Together, Arkin Capital and Arkin Bio position the organization as a long-term partner for science-driven innovation, combining rigorous investment discipline with deep operational and clinical insight across the life sciences value chain.
Arkin Bio is a global life sciences venture capital platform spanning early- and late-stage biotechnology through its two complementary strategies: Arkin Bio Ventures (early stage) and Arkin Bio Capital (late stage). Backed by deep scientific expertise, long-standing industry relationships, and a broad international collaborator network, Arkin Bio supports the development of high-impact life science companies worldwide.
Since launching its first dedicated biotech fund in 2016, Arkin Bio has invested in dozens of ventures and delivered multiple successful exits via IPOs and acquisitions. Portfolio companies include UroGen Pharma, Bluejay Therapeutics, Keros Therapeutics, Censa Pharmaceuticals, ImmPACT Bio, cCAM Biotherapeutics, and Hi-Bio.
While artificial intelligence and computational tools continue to accelerate discovery, Arkin Bio’s investment philosophy remains anchored in strong biology, disciplined translational planning, and credible clinical outcomes. Building on the foundations of Arkin Bio Ventures I (2016) and Ventures II (2020), the newly launched Arkin Bio Ventures III advances this strategy with even deeper hands-on engagement.
The fund works closely with founders from inception—shaping biological hypotheses, translational strategies, and clinical positioning—to build companies capable of achieving meaningful value inflection points. A defining feature of the approach is early alignment with downstream expectations: understanding what late-stage investors and pharmaceutical partners require, from data robustness to patient-level proof of concept, informs decisions from day one.
Arkin Bio Ventures III will invest in 10–12 companies globally, prioritizing high-potential assets in oncology, immunology, inflammation, rare diseases, and other areas of significant unmet need. With the launch of this third early-stage fund, Arkin Bio now manages more than $600 million in biotech-focused assets across early- and late-stage strategies.
The fund is led by Dr. Pini Orbach and commemorates the late Alon Lazarus, who played a central role in its formation and strategic direction.
“We launched Arkin Bio Ventures III to deepen our commitment to frontline science and the teams bringing it to life,” said Dr. Pini Orbach, Managing Partner at Arkin Bio. “This fund allows us to lean further into advanced pre-clinical opportunities and help accelerate private companies toward proof-of-concept. With our combined scientific expertise, investment discipline, and global network, we aim to be a true partner from day one.”
